Amivantamab is a Monoclonal Antibody owned by Johnson & Johnson, and is involved in 21 clinical trials, of which 1 was completed, 14 are ongoing, and 6 are planned.
Amivantamab is a bi-specific antibody. The drug candidate is epidermal growth factor receptor (EFGR) antagonist and hepatocyte growth factor receptor (c-Met) antagonist. EGFR signaling causes increased proliferation, decreased apoptosis, and enhanced tumor cell motility and neo-angiogenesis. The drug candidate prevents the binding of HGF to its receptor c-Met and subsequent activation of the HGF/c-Met signaling pathway. This results in cell death in c-Met-expressing tumor cells. The anti-proliferative activity of the drug candidate is effective for the treatment of cancer.
The revenue for Amivantamab is expected to reach a total of $10.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Amivantamab NPV Report.
Amivantamab was originated by Janssen Research & Development and Genmab and is currently owned by Johnson & Johnson.
Amivantamab Overview
Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology. It is formulated as solution and concentrate for solution for intravenous infusion. Amivantamab is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Amivantamab is under development for the treatment of non-small-cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), metastatic colorectal cancer, esophageal cancer, renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC). It is administered as an intravenous and subcutaneous infusion. The drug candidate is a bi-specific monoclonal antibody that targets EGFr and cMet with exon-20 insertion. It is based on DuoBody technology platform. The drug candidate is a new molecular entity (NME).
Johnson & Johnson Overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020.
The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.
Quick View – Amivantamab
Source link
#Revenue #Amivantamab #expected #CAGR
